Cancer Genetics of Human Gastric Adenocarcinoma

  • Roman GalyshJr.
  • Steven M. Powell


Gastric Cancer Gastric Carcinoma Hepatocyte Growth Factor Gastric Cancer Patient Familial Adenomatous Polyposis 


  1. Aarnio, M., Salovaara, R., Aaltonen, L. A., Mecklin, J. P., and Jarvinen, H. J. 1997. Features of gastric cancer in hereditary non-polyposis colorectal cancer syndrome. Int J Cancer, 74(5): 551–5.PubMedGoogle Scholar
  2. Aird, I., Bentall, H. H., and Roberts, J. A. 1953. A relationship between cancer of stomach and the ABO blood groups. Br Med J, 1(4814): 799–801.PubMedGoogle Scholar
  3. Antommarchi F. 1825. Les derniers moments de napoleon, en compement du memorial de sainte-helene. 1st ed. Brussels: H. Tarlier.Google Scholar
  4. Aoki, M., Yamamoto, K., Noshiro, H., Sakai, K., Yokota, J., Kohno, T., Tokino, T., Ishida, S., Ohyama, S., Ninomiya, I., Uesaka, K., Kitajima, M., Shimada, S., Matsuno, S., Yano, M., Hiratsuka, M., Sugimura, H., Itoh, F., Minamoto, T., Maehara, Y., Takenoshita, S., Aikou, T., Katai, H., Yoshimura, K., Takahashi, T., Akagi, K., Sairenji, M., Yamamura, Y., and Sasazuki, T. 2005. A full genome scan for gastric cancer. J Med Genet, 42(1): 83–7.PubMedGoogle Scholar
  5. Ascano, J. J., Frierson, H., Jr., Moskaluk, C. A., Harper, J. C., Roviello, F., Jackson, C. E., El-Rifai, W., Vindigni, C., Tosi, P., and Powell, S. M. 2001. Inactivation of the E-cadherin gene in sporadic diffuse-type gastric cancer. Mod Pathol, 14(10): 942–9.PubMedGoogle Scholar
  6. Baffa, R., Veronese, M. L., Santoro, R., Mandes, B., Palazzo, J. P., Rugge, M., Santoro, E., Croce, C. M., and Huebner, K. 1998. Loss of FHIT expression in gastric carcinoma. Cancer Res, 58(20): 4708–14.PubMedGoogle Scholar
  7. Barrett, M. T., Sanchez, C. A., Galipeau, P. C., Neshat, K., Emond, M., and Reid, B. J. 1996. Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus. Oncogene, 13(9): 1867–73.PubMedGoogle Scholar
  8. Becker, K. F., Atkinson, M. J., Reich, U., Becker, I., Nekarda, H., Siewert, J. R., and Hofler, H. 1994. E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. Cancer Res, 54(14): 3845–52.PubMedGoogle Scholar
  9. Beckler, A. D., Roche, J. K., Harper, J. C., Petroni, G., Frierson, H. F., Jr., Moskaluk, C. A., El-Rifai, W., and Powell, S. M. 2003. Decreased abundance of trefoil factor 1 transcript in the majority of gastric carcinomas. Cancer, 98(10): 2184–91.PubMedGoogle Scholar
  10. Belkhiri, A., Zaika, A., Pidkovka, N., Knuutila, S., Moskaluk, C., and El-Rifai, W. 2005. Darpp-32: a novel antiapoptotic gene in upper gastrointestinal carcinomas. Cancer Res, 65(15): 6583–92.PubMedGoogle Scholar
  11. Berx, G., Becker, K. F., Hofler, H., and van Roy, F. 1998. Mutations of the human E-cadherin (CDH1) gene. Hum Mutat, 12(4): 226–37.PubMedGoogle Scholar
  12. Birchmeier, W., and Behrens, J. 1994. Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. Biochim Biophys Acta, 1198(1): 11–26.PubMedGoogle Scholar
  13. Bizari, L., Borim, A. A., Leite, K. R., Goncalves Fde, T., Cury, P. M., Tajara, E. H., and Silva, A. E. 2006. Alterations of the CCND1 and HER-2/neu (ERBB2) proteins in esophageal and gastric cancers. Cancer Genet Cytogenet, 165(1): 41–50.PubMedGoogle Scholar
  14. Blair, V., Martin, I., Shaw, D., Winship, I., Kerr, D., Arnold, J., Harawira, P., McLeod, M., Parry, S., Charlton, A., Findlay, M., Cox, B., Humar, B., More, H., and Guilford, P. 2006. Hereditary diffuse gastric cancer: Diagnosis and management. Clin Gastroenterol Hepatol, 4(3): 262–75.PubMedGoogle Scholar
  15. Boren, T., Falk, P., Roth, K. A., Larson, G., and Normark, S. 1993. Attachment of helicobacter pylori to human gastric epithelium mediated by blood group antigens. Science, 262(5141): 1892–5.PubMedGoogle Scholar
  16. Boussioutas, A., Li, H., Liu, J., Waring, P., Lade, S., Holloway, A. J., Taupin, D., Gorringe, K., Haviv, I., Desmond, P. V., and Bowtell, D. D. 2003. Distinctive patterns of gene expression in premalignant gastric mucosa and gastric cancer. Cancer Res, 63(10): 2569–77.PubMedGoogle Scholar
  17. Buckwalter, J. A., Wohlwend, C. B., Colter, D. C., Tidrick, R. T., and Knowler, L. A. 1957. The association of the ABO blood groups to gastric carcinoma. Surg Gynecol Obstet, 104(2): 176–9.PubMedGoogle Scholar
  18. Burgart, L. J., Zheng, J., Shu, Q., Strickler, J. G., and Shibata, D. 1995. Somatic mitochondrial mutation in gastric cancer. Am J Pathol, 147(4): 1105–11.PubMedGoogle Scholar
  19. Caldas, C., Carneiro, F., Lynch, H. T., Yokota, J., Wiesner, G. L., Powell, S. M., Lewis, F. R., Huntsman, D. G., Pharoah, P. D., Jankowski, J. A., MacLeod, P., Vogelsang, H., Keller, G., Park, K. G., Richards, F. M., Maher, E. R., Gayther, S. A., Oliveira, C., Grehan, N., Wight, D., Seruca, R., Roviello, F., Ponder, B. A., and Jackson, C. E. 1999. Familial gastric cancer: overview and guidelines for management. J Med Genet, 36(12): 873–80.PubMedGoogle Scholar
  20. Calnan, D. P., Westley, B. R., May, F. E., Floyd, D. N., Marchbank, T., and Playford, R. J. 1999. The trefoil peptide TFF1 inhibits the growth of the human gastric adenocarcinoma cell line AGS. J Pathol, 188(3): 312–7.PubMedGoogle Scholar
  21. Candidus, S., Bischoff, P., Becker, K. F., and Hofler, H. 1996. No evidence for mutations in the alpha- and beta-catenin genes in human gastric and breast carcinomas. Cancer Res, 56(1): 49–52.PubMedGoogle Scholar
  22. Carvalho, F., Seruca, R., David, L., Amorim, A., Seixas, M., Bennett, E., Clausen, H., and Sobrinho-Simoes, M. 1997. MUC1 gene polymorphism and gastric cancer: an epidemiological study. Glycoconjug J, 14(1): 107–11.Google Scholar
  23. Cascinu, S., Graziano, F., Del Ferro, E., Staccioli, M. P., Ligi, M., Carnevali, A., Muretto, P., and Catalano, G. 1998. Expression of p53 protein and resistance to preoperative chemotherapy in locally advanced gastric carcinoma. Cancer, 83(9): 1917–22.PubMedGoogle Scholar
  24. Chariyalertsak, S., Sugano, K., Ohkura, H., and Mori, Y. 1994. Comparison of c-erbB-2 oncoprotein expression in tissue and serum of patients with stomach cancer. Tumour Biol, 15(5): 294–303.PubMedGoogle Scholar
  25. Chausovsky, G., Luchansky, M., Figer, A., Shapira, J., Gottfried, M., Novis, B., Bogelman, G., Zemer, R., Zimlichman, S., and Klein, A. 1999. Expression of cytokeratin 20 in the blood of patients with disseminated carcinoma of the pancreas, colon, stomach, and lung. Cancer, 86(11): 2398–405.PubMedGoogle Scholar
  26. Chi, X. Z., Yang, J. O., Lee, K. Y., Ito, K., Sakakura, C., Li, Q. L., Kim, H. R., Cha, E. J., Lee, Y. H., Kaneda, A., Ushijima, T., Kim, W. J., Ito, Y., and Bae, S. C. 2005. RUNX3 suppresses gastric epithelial cell growth by inducing p21(WAF1/Cip1) expression in cooperation with transforming growth factor α-activated SMAD. Mol Cell Biol, 25(18): 8097–107.PubMedGoogle Scholar
  27. Dellavecchia, C., Guala, A., Olivieri, C., Haintink, O., Cadario, F., Luinetti, O., Fiocca, R., Minelli, A., Danesino, C., and Bona, G. 1999. Early onset of gastric carcinoma and constitutional deletion of 18p. Cancer Genet Cytogenet, 113(1): 96–9.PubMedGoogle Scholar
  28. DeMatteo, R. P. 2002. The GIST of targeted cancer therapy: A tumor (gastrointestinal stromal tumor), a mutated gene (c-kit), and a molecular inhibitor (STI571). Ann Surg Oncol, 9(9): 831–9.PubMedGoogle Scholar
  29. Demetri, G. D. 2001. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options. Semin Oncol, 28(5 Suppl 17): 19–26.PubMedGoogle Scholar
  30. De Vita, F., Orditura, M., Galizia, G., Romano, C., Infusino, S., Auriemma, A., Lieto, E., and Catalano, G. 1999. Serum interleukin-10 levels in patients with advanced gastrointestinal malignancies. Cancer, 86(10): 1936–43.PubMedGoogle Scholar
  31. dos Santos, N. R., Seruca, R., Constancia, M., Seixas, M., and Sobrinho-Simoes, M. 1996. Microsatellite instability at multiple loci in gastric carcinoma: clinicopathologic implications and prognosis. Gastroenterology, 110(1): 38–44.PubMedGoogle Scholar
  32. El-Omar, E. M., Carrington, M., Chow, W. H., McColl, K. E., Bream, J. H., Young, H. A., Herrera, J., Lissowska, J., Yuan, C. C., Rothman, N., Lanyon, G., Martin, M., Fraumeni, J. F., Jr., and Rabkin, C. S. 2000. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature, 404(6776): 398–402.PubMedGoogle Scholar
  33. El-Omar, E. M., Rabkin, C. S., Gammon, M. D., Vaughan, T. L., Risch, H. A., Schoenberg, J. B., Stanford, J. L., Mayne, S. T., Goedert, J., Blot, W. J., Fraumeni, J. F., Jr., and Chow, W. H. 2003. Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology, 124(5): 1193–201.PubMedGoogle Scholar
  34. El-Rifai, W., Harper, J. C., Cummings, O. W., Hyytinen, E. R., Frierson, H. F., Jr., Knuutila, S., and Powell, S. M. 1998. Consistent genetic alterations in xenografts of proximal stomach and gastro-esophageal junction adenocarcinomas. Cancer Res, 58(1): 34–7.PubMedGoogle Scholar
  35. El-Rifai, W., Moskaluk, C. A., Abdrabbo, M. K., Harper, J., Yoshida, C., Riggins, G. J., Frierson, H. F., Jr., and Powell, S. M. 2002a. Gastric cancers overexpress S100A calcium-binding proteins. Cancer Res, 62(23): 6823–6.Google Scholar
  36. El-Rifai, W., Smith, M. F., Jr., Li, G., Beckler, A., Carl, V. S., Montgomery, E., Knuutila, S., Moskaluk, C. A., Frierson, H. F., Jr., and Powell, S. M. 2002b. Gastric cancers overexpress DARPP-32 and a novel isoform, t-DARPP. Cancer Res, 62(14): 4061–4.Google Scholar
  37. Fleisher, A. S., Esteller, M., Wang, S., Tamura, G., Suzuki, H., Yin, J., Zou, T. T., Abraham, J. M., Kong, D., Smolinski, K. N., Shi, Y. Q., Rhyu, M. G., Powell, S. M., James, S. P., Wilson, K. T., Herman, J. G., and Meltzer, S. J. 1999. Hypermethylation of the hMLH1 gene promoter in human gastric cancers with microsatellite instability. Cancer Res, 59(5): 1090–5.PubMedGoogle Scholar
  38. Friess, H., Fukuda, A., Tang, W. H., Eichenberger, A., Furlan, N., Zimmermann, A., Korc, M., and Buchler, M. W. 1999. Concomitant analysis of the epidermal growth factor receptor family in esophageal cancer: overexpression of epidermal growth factor receptor mRNA but not of c-erbB-2 and c-erbB-3. World J Surg, 23(10): 1010–8.PubMedGoogle Scholar
  39. Fukaya, M., Isohata, N., Ohta, H., Aoyagi, K., Ochiya, T., Saeki, N., Yanagihara, K., Nakanishi, Y., Taniguchi, H., Sakamoto, H., Shimoda, T., Nimura, Y., Yoshida, T., and Sasaki, H. 2006. Hedgehog signal activation in gastric pit cell and in diffuse-type gastric cancer. Gastroenterology, 131(1): 14–29.PubMedGoogle Scholar
  40. Gabbert, H. E., Muller, W., Schneiders, A., Meier, S., and Hommel, G. 1995. The relationship of p53 expression to the prognosis of 418 patients with gastric carcinoma. Cancer, 76(5): 720–6.PubMedGoogle Scholar
  41. Ganesh, S., Sier, C. F., Heerding, M. M., van Krieken, J. H., Griffioen, G., Welvaart, K., van de Velde, C. J., Verheijen, J. H., Lamers, C. B., and Verspaget, H. W. 1996. Prognostic value of the plasminogen activation system in patients with gastric carcinoma. Cancer, 77(6): 1035–43.PubMedGoogle Scholar
  42. Gayther, S. A., Gorringe, K. L., Ramus, S. J., Huntsman, D., Roviello, F., Grehan, N., Machado, J. C., Pinto, E., Seruca, R., Halling, K., MacLeod, P., Powell, S. M., Jackson, C. E., Ponder, B. A., and Caldas, C. 1998. Identification of germ-line E-cadherin mutations in gastric cancer families of European origin. Cancer Res, 58(18): 4086–9.PubMedGoogle Scholar
  43. Gemma, A., Hagiwara, K., Ke, Y., Burke, L. M., Khan, M. A., Nagashima, M., Bennett, W. P., and Harris, C. C. 1997. FHIT mutations in human primary gastric cancer. Cancer Res, 57(8): 1435–7.PubMedGoogle Scholar
  44. Gil, J., Yamamoto, H., Zapata, J. M., Reed, J. C., and Perucho, M. 1999. Impairment of the proapoptotic activity of bax by missense mutations found in gastrointestinal cancers. Cancer Res, 59(9): 2034–7.PubMedGoogle Scholar
  45. Gofuku, J., Shiozaki, H., Doki, Y., Inoue, M., Hirao, M., Fukuchi, N., and Monden, M. 1998. Characterization of soluble E-cadherin as a disease marker in gastric cancer patients. Br J Cancer, 78(8): 1095–101.PubMedGoogle Scholar
  46. Goldgar, D. E., Easton, D. F., Cannon-Albright, L. A., and Skolnick, M. H. 1994. Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst, 86(21): 1600–8.PubMedGoogle Scholar
  47. Gorer, P. A. 1938. Genetic interpretation of studies on cancer in twins. Ann Eugen, 8: 219.Google Scholar
  48. Groden, J., Thliveris, A., Samowitz, W., Carlson, M., Gelbert, L., Albertsen, H., Joslyn, G., Stevens, J., Spirio, L., and Robertson, M. 1991. Identification and characterization of the familial adenomatous polyposis coli gene. Cell, 66(3): 589–600.PubMedGoogle Scholar
  49. Gschwind, A., Fischer, O. M., and Ullrich, A. 2004. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nature reviews. Cancer, 4(5): 361–70.PubMedGoogle Scholar
  50. Guan, X. Y., Fu, S. B., Xia, J. C., Fang, Y., Sham, J. S., Du, B. D., Zhou, H., Lu, S., Wang, B. Q., Lin, Y. Z., Liang, Q., Li, X. M., Du, B., Ning, X. M., Du, J. R., Li, P., and Trent, J. M. 2000. Recurrent chromosome changes in 62 primary gastric carcinomas detected by comparative genomic hybridization. Cancer Genet Cytogenet, 123(1): 27–34.PubMedGoogle Scholar
  51. Guilford, P., Hopkins, J., Harraway, J., McLeod, M., McLeod, N., Harawira, P., Taite, H., Scoular, R., Miller, A., and Reeve, A. E. 1998. E-cadherin germline mutations in familial gastric cancer. Nature, 392(6674): 402–5.PubMedGoogle Scholar
  52. Hachisuka, T., Narikiyo, M., Yamada, Y., Ishikawa, H., Ueno, M., Uchida, H., Yoriki, R., Ohigashi, Y., Miki, K., Tamaki, H., Mizuno, T., and Nakajima, Y. 2005. High lymphatic vessel density correlates with overexpression of VEGF-C in gastric cancer. Oncol Rep, 13(4): 733–7.PubMedGoogle Scholar
  53. Halling, K. C., Harper, J., Moskaluk, C. A., Thibodeau, S. N., Petroni, G. R., Yustein, A. S., Tosi, P., Minacci, C., Roviello, F., Piva, P., Hamilton, S. R., Jackson, C. E., and Powell, S. M. 1999. Origin of microsatellite instability in gastric cancer. Am J Pathol, 155(1): 205–11.PubMedGoogle Scholar
  54. Han, S., Kim, H. Y., Park, K., Cho, H. J., Lee, M. S., Kim, H. J., and Kim, Y. D. 1999a. c-myc expression is related with cell proliferation and associated with poor clinical outcome in human gastric cancer. J Korean Med Sci, 14(5): 526–30.Google Scholar
  55. Han, S. U., Lee, J. H., Kim, W. H., Cho, Y. K., and Kim, M. W. 1999b. Significant correlation between serum level of hepatocyte growth factor and progression of gastric carcinoma. World J Surg, 23(11): 1176–80.Google Scholar
  56. Hara, T., Ooi, A., Kobayashi, M., Mai, M., Yanagihara, K., and Nakanishi, I. 1998. Amplification of c-myc, K-sam, and c-met in gastric cancers: Detection by fluorescence in situ hybridization. Lab Invest, 78(9): 1143–53.PubMedGoogle Scholar
  57. Hemminki, K., and Jiang, Y. 2002. Familial and second gastric carcinomas: a nationwide epide-miologic study from Sweden. Cancer, 94(4): 1157–65.PubMedGoogle Scholar
  58. Henry, J. A., Bennett, M. K., Piggott, N. H., Levett, D. L., May, F. E., and Westley, B. R. 1991. Expression of the pNR-2/pS2 protein in diverse human epithelial tumours. Br J Cancer, 64(4): 677–82.PubMedGoogle Scholar
  59. Hidaka, S., Yasutake, T., Kondo, M., Takeshita, H., Yano, H., Haseba, M., Tsuji, T., Sawai, T., Nakagoe, T., and Tagawa, Y. 2003. Frequent gains of 20q and losses of 18q are associated with lymph node metastasis in intestinal-type gastric cancer. Anticancer Res, 23(4): 3353–7.PubMedGoogle Scholar
  60. Hippo, Y., Taniguchi, H., Tsutsumi, S., Machida, N., Chong, J. M., Fukayama, M., Kodama, T., and Aburatani, H. 2002. Global gene expression analysis of gastric cancer by oligonucleotide microarrays. Cancer Res, 62(1): 233–40.PubMedGoogle Scholar
  61. Hirata, T., Yamamoto, H., Taniguchi, H., Horiuchi, S., Oki, M., Adachi, Y., Imai, K., and Shinomura, Y. 2007. Characterization of the immune escape phenotype of human gastric cancers with and without high-frequency microsatellite instability. J Pathol, 211(5): 516–23.PubMedGoogle Scholar
  62. Hiyama, E., Yokoyama, T., Tatsumoto, N., Hiyama, K., Imamura, Y., Murakami, Y., Kodama, T., Piatyszek, M. A., Shay, J. W., and Matsuura, Y. 1995. Telomerase activity in gastric cancer. Cancer Res, 55(15): 3258–62.PubMedGoogle Scholar
  63. Hizawa, K., Iida, M., Yao, T., Aoyagi, K., and Fujishima, M. 1997. Juvenile polyposis of the stomach: clinicopathological features and its malignant potential. J Clin Pathol, 50(9): 771–4.PubMedGoogle Scholar
  64. Hofgartner, W. T., Thorp, M., Ramus, M. W., Delorefice, G., Chey, W. Y., Ryan, C. K., Takahashi, G. W., and Lobitz, J. R. 1999. Gastric adenocarcinoma associated with fundic gland polyps in a patient with attenuated familial adenomatous polyposis. Am J Gastroenterol, 94(8): 2275–81.PubMedGoogle Scholar
  65. Hold, G. L., Rabkin, C. S., Chow, W. H., Smith, M. G., Gammon, M. D., Risch, H. A., Vaughan, T. L., McColl, K. E., Lissowska, J., Zatonski, W., Schoenberg, J. B., Blot, W. J., Mowat, N. A., Fraumeni, J. F., Jr., and El-Omar, E. M. 2007. A functional polymorphism of toll-like receptor 4 gene increases risk of gastric carcinoma and its precursors. Gastroenterology, 132(3): 905–12.PubMedGoogle Scholar
  66. Hollstein, M., Shomer, B., Greenblatt, M., Soussi, T., Hovig, E., Montesano, R., and Harris, C. C. 1996. Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation. Nucl Acids Res, 24(1): 141–6.PubMedGoogle Scholar
  67. Howlett, M., Judd, L. M., Jenkins, B., La Gruta, N. L., Grail, D., Ernst, M., and Giraud, A. S. 2005. Differential regulation of gastric tumor growth by cytokines that signal exclusively through the coreceptor gp130. Gastroenterology, 129(3): 1005–18.PubMedGoogle Scholar
  68. Hurlimann, J., and Saraga, E. P. 1994. Expression of p53 protein in gastric carcinomas: association with histologic type and prognosis. Am J Surg Pathol, 18(12): 1247–53.PubMedGoogle Scholar
  69. Iacopetta, B. J., Soong, R., House, A. K., and Hamelin, R. 1999. Gastric carcinomas with micros-atellite instability: clinical features and mutations to the TGF-beta type II receptor, IGFII receptor, and BAX genes. J Pathol, 187(4): 428–32.PubMedGoogle Scholar
  70. Igaki, H., Sasaki, H., Tachimori, Y., Kato, H., Watanabe, H., Kimura, T., Harada, Y., Sugimura, T., and Terada, M. 1995. Mutation frequency of the p16/CDKN2 gene in primary cancers in the upper digestive tract. Cancer Res, 55(15): 3421–3.PubMedGoogle Scholar
  71. Inoue, T., Chung, Y. S., Yashiro, M., Nishimura, S., Hasuma, T., Otani, S., and Sowa, M. 1997. Transforming growth factor-beta and hepatocyte growth factor produced by gastric fibroblasts stimulate the invasiveness of scirrhous gastric cancer cells. Jpn J Cancer Res, 88(2): 152–9.PubMedGoogle Scholar
  72. Ito, K., Liu, Q., Salto-Tellez, M., Yano, T., Tada, K., Ida, H., Huang, C., Shah, N., Inoue, M., Rajnakova, A., Hiong, K. C., Peh, B. K., Han, H. C., Ito, T., Teh, M., Yeoh, K. G., and Ito, Y. 2005. RUNX3, a novel tumor suppressor, is frequently inactivated in gastric cancer by protein mislocalization. Cancer Res, 65(17): 7743–50.PubMedGoogle Scholar
  73. Ito, H., Yonemura, Y., Fujita, H., Tsuchihara, K., Kawamura, T., Nojima, N., Fujimura, T., Nose, H., Endo, Y., and Sasaki, T. 1996. Prognostic relevance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in gastric cancer. Virchows Arch, 427(5): 487–96.PubMedGoogle Scholar
  74. Jang, S. J., Park, Y. W., Park, M. H., Lee, J. D., Lee, Y. Y., Jung, T. J., Kim, I. S., Choi, I. Y., Ki, M., Choi, B. Y., and Ahn, M. J. 1999. Expression of cell-cycle regulators, cyclin E and p21WAF1/ CIP1, potential prognostic markers for gastric cancer. Eur J Surg Oncol, 25(2): 157–63.PubMedGoogle Scholar
  75. Jones, S., Emmerson, P., Maynard, J., Best, J. M., Jordan, S., Williams, G. T., Sampson, J. R., and Cheadle, J. P. 2002. Biallelic germline mutations in MYH predispose to multiple colorectal adenoma and somatic G:C→T:A mutations. Hum Mol Genet, 11(23): 2961–7.PubMedGoogle Scholar
  76. Kang, S. H., Bang, Y. J., Im, Y. H., Yang, H. K., Lee, D. A., Lee, H. Y., Lee, H. S., Kim, N. K., and Kim, S. J. 1999. Transcriptional repression of the transforming growth factor-beta type I receptor gene by DNA methylation results in the development of TGF-beta resistance in human gastric cancer. Oncogene, 18(51): 7280–6.PubMedGoogle Scholar
  77. Kastury, K., Baffa, R., Druck, T., Ohta, M., Cotticelli, M. G., Inoue, H., Negrini, M., Rugge, M., Huang, D., Croce, C. M., Palazzo, J., and Huebner, K. 1996. Potential gastrointestinal tumor suppressor locus at the 3p14.2 FRA3B site identified by homozygous deletions in tumor cell lines. Cancer Res, 56(5): 978–83.PubMedGoogle Scholar
  78. Kawanishi, J., Kato, J., Sasaki, K., Fujii, S., Watanabe, N., and Niitsu, Y. 1995. Loss of E-cadherin-dependent cell-cell adhesion due to mutation of the beta-catenin gene in a human cancer cell line, HSC-39. Mol Cell Biol, 15(3): 1175–81.PubMedGoogle Scholar
  79. Kim, C. J., Cho, Y. G., Park, C. H., Kim, S. Y., Nam, S. W., Lee, S. H., Yoo, N. J., Lee, J. Y., and Park, W. S. 2004. Genetic alterations of the MYH gene in gastric cancer. Oncogene, 23(40): 6820–2.PubMedGoogle Scholar
  80. Kim, J., Sohn, S., Chae, Y., Cho, Y., Bae, H. I., Yan, G., Park, J., Lee, M. H., Chung, H., and Yu, W. 2007. Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with gastric cancer. Ann Oncol, 18(6): 1030–6.PubMedGoogle Scholar
  81. Kimura, Y., Noguchi, T., Kawahara, K., Kashima, K., Daa, T., and Yokoyama, S. 2004. Genetic alterations in 102 primary gastric cancers by comparative genomic hybridization: gain of 20q and loss of 18q are associated with tumor progression. Mod Pathol 17(11): 1328–37.PubMedGoogle Scholar
  82. Kinzler, K. W., and Vogelstein, B. 1996. Lessons from hereditary colorectal cancer. Cell, 87(2): 159–70.PubMedGoogle Scholar
  83. Kleihues, P., Schauble, B., zur Hausen, A., Esteve, J., and Ohgaki, H. 1997. Tumors associated with p53 germline mutations: a synopsis of 91 families. Am J Pathol, 150(1): 1–13.PubMedGoogle Scholar
  84. Klump, B., Hsieh, C. J., Holzmann, K., Gregor, M., and Porschen, R. 1998. Hypermethylation of the CDKN2/p16 promoter during neoplastic progression in Barrett's esophagus. Gastroenterology, 115(6): 1381–6.PubMedGoogle Scholar
  85. Kondo, S., Shinomura, Y., Kanayama, S., Higashimoto, Y., Kiyohara, T., Yasunaga, Y., Kitamura, S., Ueyama, H., Imamura, I., and Fukui, H. 1995. Helicobacter pylori increases gene expression of hepatocyte growth factor in human gastric mucosa. Biochem Biophys Res Commun, 210(3): 960–5.PubMedGoogle Scholar
  86. Kondo, S., Shinomura, Y., Miyazaki, Y., Kiyohara, T., Tsutsui, S., Kitamura, S., Nagasawa, Y., Nakahara, M., Kanayama, S., and Matsuzawa, Y. 2000. Mutations of the bak gene in human gastric and colorectal cancers. Cancer Res, 60(16): 4328–30.PubMedGoogle Scholar
  87. Koshiba, M., Ogawa, O., Habuchi, T., Hamazaki, S., Shimada, T., Takahashi, R., and Sugiyama, T. 1993. Infrequent ras mutation in human stomach cancers. Jpn J Cancer Res, 84(2): 163–7.PubMedGoogle Scholar
  88. Kubba, A. K., and Young, M. 1999. The Napoleonic cancer gene? J Med Biogr, 7(3): 175–81.PubMedGoogle Scholar
  89. Kuniyasu, H., Yasui, W., Kitadai, Y., Yokozaki, H., Ito, H., and Tahara, E. 1992. Frequent amplification of the c-met gene in scirrhous type stomach cancer. Bioch Biophys Res Commun, 189(1): 227–32.Google Scholar
  90. Kuniyasu, H., Yasui, W., Yokozaki, H., Kitadai, Y., and Tahara, E. 1993. Aberrant expression of c-met mRNA in human gastric carcinomas. J Int Cancer, 55(1): 72–5.Google Scholar
  91. Kuraoka, K., Matsumura, S., Sanada, Y., Nakachi, K., Imai, K., Eguchi, H., Matsusaki, K., Oue, N., Nakayama, H., and Yasui, W. 2005. A single nucleotide polymorphism in the extracellular domain of TRAIL receptor DR4 at nucleotide 626 in gastric cancer patients in Japan. Oncol Rep, 14(2): 465–70.PubMedGoogle Scholar
  92. Kurihara, N., Kubota, T., Furukawa, T., Watanabe, M., Otani, Y., Kumai, K., and Kitajima, M. 1999. Chemosensitivity testing of primary tumor cells from gastric cancer patients with liver metastasis can identify effective antitumor drugs. Anticancer Res, 19(6B): 5155–8.PubMedGoogle Scholar
  93. Kuwahara, A., Katano, M., Nakamura, M., Fujimoto, K., Miyazaki, K., Mori, M., and Morisaki, T. 1999. New therapeutic strategy for gastric carcinoma: a two-step evaluation of malignant potential from its molecular biologic and pathologic characteristics. J Surg Oncol, 72(3): 142–9.PubMedGoogle Scholar
  94. Kwon, O. J., Kang, H. S., Suh, J. S., Chang, M. S., Jang, J. J., and Chung, J. K. 1999. The loss of p27 protein has an independent prognostic significance in gastric cancer. Anticancer Res, 19(5B): 4215–20.PubMedGoogle Scholar
  95. La Vecchia, C., Negri, E., Franceschi, S., and Gentile, A. 1992. Family history and the risk of stomach and colorectal cancer. Cancer, 70(1): 50–5.PubMedGoogle Scholar
  96. Lee, F. I. 1971. Carcinoma of the gastric antrum in identical twins. Postgrad Med J, 47(551): 622–4.PubMedGoogle Scholar
  97. Lee, J. H., Han, S. U., Cho, H., Jennings, B., Gerrard, B., Dean, M., Schmidt, L., Zbar, B., and Vande Woude, G. F. 2000. A novel germ line juxtamembrane met mutation in human gastric cancer. Oncogene, 19(43): 4947–53.PubMedGoogle Scholar
  98. Lee, J. W., Jeong, E. G., Lee, S. H., Nam, S. W., Kim, S. H., Lee, J. Y., Yoo, N. J., and Lee, S. H. 2007. Mutational analysis of PTPRT phosphatase domains in common human cancers. Acta Pathol Microbiol Immunol Scand, 115(1): 47–51.Google Scholar
  99. Lee, J. W., Jeong, E. G., Soung, Y. H., Nam, S. W., Lee, J. Y., Yoo, N. J., and Lee, S. H. 2006. Decreased expression of tumour suppressor bax-interacting factor-1 (bif-1), a bax activator, in gastric carcinomas. Pathology, 38(4): 312–5.PubMedGoogle Scholar
  100. Lee, K. H., Lee, J. S., Suh, C., Kim, S. W., Kim, S. B., Lee, J. H., Lee, M. S., Park, M. Y., Sun, H. S., and Kim, S. H. 1995. Clinicopathologic significance of the K-ras gene codon 12 point mutation in stomach cancer: an analysis of 140 cases. Cancer, 75(12): 2794–801.PubMedGoogle Scholar
  101. Lee, J. E., Lowy, A. M., Thompson, W. A., Lu, M., Loflin, P. T., Skibber, J. M., Evans, D. B., Curley, S. A., Mansfield, P. F., and Reveille, J. D. 1996. Association of gastric adenocarcinoma with the HLA class II gene DQB10301. Gastroenterology, 111(2): 426–32.PubMedGoogle Scholar
  102. Lefebvre, O., Chenard, M. P., Masson, R., Linares, J., Dierich, A., LeMeur, M., Wendling, C., Tomasetto, C., Chambon, P., and Rio, M. C. 1996. Gastric mucosa abnormalities and tumori-genesis in mice lacking the pS2 trefoil protein. Science, 274(5285): 259–62.PubMedGoogle Scholar
  103. Leung, S. Y., Chen, X., Chu, K. M., Yuen, S. T., Mathy, J., Ji, J., Chan, A. S., Li, R., Law, S., Troyanskaya, O. G., Tu, I. P., Wong, J., So, S., Botstein, D., and Brown, P. O. 2002. Phospholipase A2 group IIA expression in gastric adenocarcinoma is associated with prolonged survival and less frequent metastasis. Proc Natl Acad Sci USA, 99(25): 16203–8.PubMedGoogle Scholar
  104. Leung, S. Y., Yuen, S. T., Chung, L. P., Chu, K. M., Chan, A. S., and Ho, J. C. 1999. hMLH1 promoter methylation and lack of hMLH1 expression in sporadic gastric carcinomas with high-frequency microsatellite instability. Cancer Res, 59(1): 159–64.PubMedGoogle Scholar
  105. Li, F. P., and Fraumeni, J. F., Jr. 1969. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med, 71(4): 747–52.Google Scholar
  106. Li, V. S., Wong, C. W., Chan, T. L., Chan, A. S., Zhao, W., Chu, K. M., So, S., Chen, X., Yuen, S. T., and Leung, S. Y. 2005. Mutations of PIK3CA in gastric adenocarcinoma. BMC Cancer, 5: 29.PubMedGoogle Scholar
  107. Lin, W. C., Li, A. F., Chi, C. W., Chung, W. W., Huang, C. L., Lui, W. Y., Kung, H. J., and Wu, C. W. 1999. Tie-1 protein tyrosine kinase: a novel independent prognostic marker for gastric cancer. Clin Cancer Res, 5(7): 1745–51.PubMedGoogle Scholar
  108. Lindor, N. M., and Greene, M. H. 1998. The concise handbook of family cancer syndromes: Mayo familial cancer program. J Natl Cancer Inst, 90(14): 1039–71.PubMedGoogle Scholar
  109. Liu, X. P., Kawauchi, S., Oga, A., Suehiro, Y., Tsushimi, K., Tsushimi, M., and Sasaki, K. 2001. Combined examination of p27(Kip1), p21(Waf1/Cip1) and p53 expression allows precise estimation of prognosis in patients with gastric carcinoma. Histopathology, 39(6): 603–10.PubMedGoogle Scholar
  110. Lugli, A., Zlobec, I., Singer, G., Kopp Lugli, A., Terracciano, L. M., and Genta, R. M. 2007. Napoleon Bonaparte's gastric cancer: a clinicopathologic approach to staging, pathogenesis, and etiology. Nature clinical practice. Gastroenterol Hepatol, 4(1): 52–7.Google Scholar
  111. Luqmani, Y., Bennett, C., Paterson, I., Corbishley, C. M., Rio, M. C., Chambon, P., and Ryall, G. 1989. Expression of the pS2 gene in normal, benign and neoplastic human stomach. J Int Cancer, 44(5): 806–12.Google Scholar
  112. Lynch, H. T., Grady, W., Suriano, G., and Huntsman, D. 2005. Gastric cancer: new genetic developments. J Surg Oncol, 90(3): 114–33; discussion 133.PubMedGoogle Scholar
  113. Lynch, H. T., and Krush, A. J. 1971. Cancer family “G” revisited: 1895–1970. Cancer, 27(6): 1505–11.PubMedGoogle Scholar
  114. Lynch, H. T., Smyrk, T. C., Watson, P., Lanspa, S. J., Lynch, J. F., Lynch, P. M., Cavalieri, R. J., and Boland, C. R. 1993. Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review. Gastroenterology, 104(5): 1535–49.PubMedGoogle Scholar
  115. Ma, X., Chen, K., Huang, S., Zhang, X., Adegboyega, P. A., Evers, B. M., Zhang, H., and Xie, J. 2005. Frequent activation of the hedgehog pathway in advanced gastric adenocarcinomas. Carcinogenesis, 26(10): 1698–705.PubMedGoogle Scholar
  116. Machado, J. C., Carneiro, F., Blin, N., and Sobrinho-Simoes, M. 1996. Pattern of pS2 protein expression in premalignant and malignant lesions of gastric mucosa. Eur J Cancer Prev, 5(3): 169–79.PubMedGoogle Scholar
  117. Machado, J. C., Figueiredo, C., Canedo, P., Pharoah, P., Carvalho, R., Nabais, S., Castro Alves, C., Campos, M. L., Van Doorn, L. J., Caldas, C., Seruca, R., Carneiro, F., and Sobrinho-Simoes, M. 2003. A proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma. Gastroenterology, 125(2): 364–71.PubMedGoogle Scholar
  118. Machado, J. C., Soares, P., Carneiro, F., Rocha, A., Beck, S., Blin, N., Berx, G., and Sobrinho-Simoes, M. 1999. E-cadherin gene mutations provide a genetic basis for the phenotypic divergence of mixed gastric carcinomas. Lab Invest, 79(4): 459–65.PubMedGoogle Scholar
  119. Maeda, K., Kang, S. M., Onoda, N., Ogawa, M., Kato, Y., Sawada, T., and Chung, K. H. 1999. Vascular endothelial growth factor expression in preoperative biopsy specimens correlates with disease recurrence in patients with early gastric carcinoma. Cancer, 86(4): 566–71.PubMedGoogle Scholar
  120. Maesawa, C., Tamura, G., Suzuki, Y., Ogasawara, S., Sakata, K., Kashiwaba, M., and Satodate, R. 1995. The sequential accumulation of genetic alterations characteristic of the colorectal adenoma-carcinoma sequence does not occur between gastric adenoma and adenocarcinoma. J Pathol, 176(3): 249–58.PubMedGoogle Scholar
  121. Maimon, S. N., and Zinninger, M. M. 1953. Familial gastric cancer. Gastroenterology, 25(2): 139–52; discussion, 153–5.PubMedGoogle Scholar
  122. Marrelli, D., Roviello, F., De Stefano, A., Farnetani, M., Garosi, L., Messano, A., and Pinto, E. 1999. Prognostic significance of CEA, CA 19-9 and CA 72-4 preoperative serum levels in gastric carcinoma. Oncology, 57(1): 55–62.PubMedGoogle Scholar
  123. Massad, M., Uthman, S., Obeid, S., and Majjar, F. 1990. Ataxia-telangiectasia and stomach cancer. Am J Gastroenterol, 85(5): 630–1.PubMedGoogle Scholar
  124. Matsui, S., Shiozaki, H., Inoue, M., Tamura, S., Doki, Y., Kadowaki, T., Iwazawa, T., Shimaya, K., Nagafuchi, A., and Tsukita, S. 1994. Immunohistochemical evaluation of alpha-catenin expression in human gastric cancer. Virchows Arch, 424(4): 375–81.PubMedGoogle Scholar
  125. Mayer, B., Johnson, J. P., Leitl, F., Jauch, K. W., Heiss, M. M., Schildberg, F. W., Birchmeier, W., and Funke, I. 1993. E-cadherin expression in primary and metastatic gastric cancer: down-regulation correlates with cellular dedifferentiation and glandular disintegration. Cancer Res, 53(7): 1690–5.PubMedGoogle Scholar
  126. Miao, X., Zhang, X., Zhang, L., Guo, Y., Hao, B., Tan, W., He, F., and Lin, D. 2006. Adenosine diphosphate ribosyl transferase and x-ray repair cross-complementing 1 polymorphisms in gastric cardia cancer. Gastroenterology, 131(2): 420–7.PubMedGoogle Scholar
  127. Mizutani, T., Onda, M., Tokunaga, A., Yamanaka, N., and Sugisaki, Y. 1993. Relationship of C-erbB-2 protein expression and gene amplification to invasion and metastasis in human gastric cancer. Cancer, 72(7): 2083–8.PubMedGoogle Scholar
  128. Mori, Y., Sato, F., Selaru, F. M., Olaru, A., Perry, K., Kimos, M. C., Tamura, G., Matsubara, N., Wang, S., Xu, Y., Yin, J., Zou, T. T., Leggett, B., Young, J., Nukiwa, T., Stine, O. C., Abraham, J. M., Shibata, D., and Meltzer, S. J. 2002. Instabilotyping reveals unique muta-tional spectra in microsatellite-unstable gastric cancers. Cancer Res, 62(13): 3641–5.PubMedGoogle Scholar
  129. Morin, P. J. 1999. Beta-catenin signaling and cancer. Bioessays, 21(12): 1021–30.PubMedGoogle Scholar
  130. Morris, L. E., Bloom, G. S., Frierson, H. F., Jr., and Powell, S. M. 2005. Nucleotide variants within the IQGAP1 gene in diffuse-type gastric cancers. Genes Chromosomes Cancer, 42(3): 280–6.PubMedGoogle Scholar
  131. Moskaluk, C. A., Hu, J., and Perlman, E. J. 1998. Comparative genomic hybridization of esopha-geal and gastroesophageal adenocarcinomas shows consensus areas of DNA gain and loss. Genes Chromosomes Cancer, 22(4): 305–11.PubMedGoogle Scholar
  132. Muguruma, K., Nakata, B., Hirakawa, K., Yamashita, Y., Onoda, N., Inoue, T., Matsuoka, T., Kato, Y., and Sowa, M. 1998. p53 and bax protein expression as predictor of chemotherapeutic effect in gastric carcinoma. Cancer Chemother, 25(Suppl 3): 400–3.Google Scholar
  133. Muller, W., and Borchard, F. 1993. pS2 protein in gastric carcinoma and normal gastric mucosa: association with clinicopathological parameters and patient survival. J Pathol, 171(4): 263–9.PubMedGoogle Scholar
  134. Myeroff, L. L., Parsons, R., Kim, S. J., Hedrick, L., Cho, K. R., Orth, K., Mathis, M., Kinzler, K. W., Lutterbaugh, J., and Park, K. 1995. A transforming growth factor beta receptor type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability. Cancer Res, 55(23): 5545–7.PubMedGoogle Scholar
  135. Nagahara, H., Mimori, K., Utsunomiya, T., Barnard, G. F., Ohira, M., Hirakawa, K., and Mori, M. 2005. Clinicopathologic and biological significance of kallikrein 6 overexpression in human gastric cancer. Clin Cancer Res, 11(19 Pt 1): 6800–6.PubMedGoogle Scholar
  136. Nagase, H., and Nakamura, Y. 1993. Mutations of the APC (adenomatous polyposis coli) gene. Hum Mutat, 2(6): 425–34.PubMedGoogle Scholar
  137. Nakajima, M., Sawada, H., Yamada, Y., Watanabe, A., Tatsumi, M., Yamashita, J., Matsuda, M., Sakaguchi, T., Hirao, T., and Nakano, H. 1999. The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer, 85(9): 1894–902.PubMedGoogle Scholar
  138. Nakamura, K., Yashiro, M., Matsuoka, T., Tendo, M., Shimizu, T., Miwa, A., and Hirakawa, K. 2006. A novel molecular targeting compound as K-samII/FGF-R2 phosphorylation inhibitor, Ki23057, for scirrhous gastric cancer. Gastroenterology, 131(5): 1530–41.PubMedGoogle Scholar
  139. Nakata, B., Hirakawa-YS Chung, K., Kato, Y., Yamashita, Y., Maeda, K., Onoda, N., Sawada, T., and Sowa, M. 1998a. Serum CA 125 level as a predictor of peritoneal dissemination in patients with gastric carcinoma. Cancer, 83(12): 2488–92.Google Scholar
  140. Nakata, B., Muguruma, K., Hirakawa, K., Chung, Y. S., Yamashita, Y., Inoue, T., Matsuoka, T., Onoda, N., Kato, Y., and Sowa, M. 1998b. Predictive value of bcl-2 and bax protein expression for chemotherapeutic effect in gastric cancer. A pilot study. Oncology, 55(6): 543–7.Google Scholar
  141. Nishigaki, R., Osaki, M., Hiratsuka, M., Toda, T., Murakami, K., Jeang, K. T., Ito, H., Inoue, T., and Oshimura, M. 2005. Proteomic identification of differentially-expressed genes in human gastric carcinomas. Proteomics, 5(12): 3205–13.PubMedGoogle Scholar
  142. Nishizuka, S., Tamura, G., Terashima, M., and Satodate, R. 1998. Loss of heterozygosity during the development and progression of differentiated adenocarcinoma of the stomach. J Pathol, 185(1): 38–43.PubMedGoogle Scholar
  143. Nogueira, A. M., Machado, J. C., Carneiro, F., Reis, C. A., Gott, P., and Sobrinho-Simoes, M. 1999. Patterns of expression of trefoil peptides and mucins in gastric polyps with and without malignant transformation. J Pathol, 187(5): 541–8.PubMedGoogle Scholar
  144. Oda, T., Kanai, Y., Oyama, T., Yoshiura, K., Shimoyama, Y., Birchmeier, W., Sugimura, T., and Hirohashi, S. 1994. E-cadherin gene mutations in human gastric carcinoma cell lines. Proc Natl Acad Sci USA, 91(5): 1858–62.PubMedGoogle Scholar
  145. Offerhaus, G. J., Giardiello, F. M., Krush, A. J., Booker, S. V., Tersmette, A. C., Kelley, N. C., and Hamilton, S. R. 1992. The risk of upper gastrointestinal cancer in familial adenomatous polyposis. Gastroenterology, 102(6): 1980–2.PubMedGoogle Scholar
  146. Ogasawara, S., Maesawa, C., Tamura, G., and Satodate, R. 1994. Lack of mutations of the adenomatous polyposis coli gene in oesophageal and gastric carcinomas. Virchows Arch, 424(6): 607–11.PubMedGoogle Scholar
  147. Ohta, M., Inoue, H., Cotticelli, M. G., Kastury, K., Baffa, R., Palazzo, J., Siprashvili, Z., Mori, M., McCue, P., Druck, T., Croce, C. M., and Huebner, K. 1996. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell, 84(4): 587–97.PubMedGoogle Scholar
  148. Oliveira, C., Seruca, R., Seixas, M., and Sobrinho-Simoes, M. 1998. The clinicopathological features of gastric carcinomas with microsatellite instability may be mediated by mutations of different “target genes”: a study of the TGFbeta RII, IGFII R, and BAX genes. Am J Pathol, 153(4): 1211–9.PubMedGoogle Scholar
  149. Ottini, L., Falchetti, M., D'Amico, C., Amorosi, A., Saieva, C., Masala, G., Frati, L., Cama, A., Palli, D., and Mariani-Costantini, R. 1998. Mutations at coding mononucleotide repeats in gastric cancer with the microsatellite mutator phenotype. Oncogene, 16(21): 2767–72.PubMedGoogle Scholar
  150. Ottini, L., Palli, D., Falchetti, M., D'Amico, C., Amorosi, A., Saieva, C., Calzolari, A., Cimoli, F., Tatarelli, C., De Marchis, L., Masala, G., Mariani-Costantini, R., and Cama, A. 1997. Microsatellite instability in gastric cancer is associated with tumor location and family history in a high-risk population from Tuscany. Cancer Res, 57(20): 4523–9.PubMedGoogle Scholar
  151. Ouyang, H., Furukawa, T., Abe, T., Kato, Y., and Horii, A. 1998. The BAX gene, the promoter of apoptosis, is mutated in genetically unstable cancers of the colorectum, stomach, and endometrium. Clin Cancer Res, 4(4): 1071–4.PubMedGoogle Scholar
  152. Palli, D., Galli, M., Caporaso, N. E., Cipriani, F., Decarli, A., Saieva, C., Fraumeni, J. F., Jr., and Buiatti, E. 1994. Family history and risk of stomach cancer in Italy. Cancer Epidemiol Biomarkers Prev, 3(1): 15–8.PubMedGoogle Scholar
  153. Panani, A. D., Ferti, A., Malliaros, S., and Raptis, S. 1995. Cytogenetic study of 11 gastric adeno-carcinomas. Cancer Genet Cytogenet, 81(2): 169–72.PubMedGoogle Scholar
  154. Park, K., Kim, S. J., Bang, Y. J., Park, J. G., Kim, N. K., Roberts, A. B., and Sporn, M. B. 1994. Genetic changes in the transforming growth factor beta (TGF-beta) type II receptor gene in human gastric cancer cells: correlation with sensitivity to growth inhibition by TGF-beta. Proc Natl Acad Sci USA, 91(19): 8772–6.PubMedGoogle Scholar
  155. Park, G. T., Lee, O. Y., Kwon, S. J., Lee, C. G., Yoon, B. C., Hahm, J. S., Lee, M. H., Hoo Lee, D., Kee, C. S., and Sun, H. S. 2003. Analysis of CYP2E1 polymorphism for the determination of genetic susceptibility to gastric cancer in Koreans. J Gastroenterol Hepatol, 18(11): 1257–63.PubMedGoogle Scholar
  156. Park, W. S., Lee, J. H., Shin, M. S., Park, J. Y., Kim, H. S., Kim, Y. S., Park, C. H., Lee, S. K., Lee, S. H., Lee, S. N., Kim, H., Yoo, N. J., and Lee, J. Y. 2001. Inactivating mutations of KILLER/DR5 gene in gastric cancers. Gastroenterology, 121(5): 1219–25.PubMedGoogle Scholar
  157. Park, W. S., Moon, Y. W., Yang, Y. M., Kim, Y. S., Kim, Y. D., Fuller, B. G., Vortmeyer, A. O., Fogt, F., Lubensky, I. A., and Zhuang, Z. 1998. Mutations of the STK11 gene in sporadic gastric carcinoma. Int J Oncol, 13(3): 601–4.PubMedGoogle Scholar
  158. Park, W. S., Oh, R. R., Park, J. Y., Lee, S. H., Shin, M. S., Kim, Y. S., Kim, S. Y., Lee, H. K., Kim, P. J., Oh, S. T., Yoo, N. J., and Lee, J. Y. 1999. Frequent somatic mutations of the beta-catenin gene in intestinal-type gastric cancer. Cancer Res, 59(17): 4257–60.PubMedGoogle Scholar
  159. Pituch-Noworolska, A., Wieckiewicz, J., Krzeszowiak, A., Stachura, J., Ruggiero, I., Gawlicka, M., Szczepanik, A., Karcz, D., Popiela, T., and Zembala, M. 1998. Evaluation of circulating tumour cells expressing CD44 variants in the blood of gastric cancer patients by flow cytometry. Anticancer Res, 18(5B): 3747–52.PubMedGoogle Scholar
  160. Poon, T. C., Sung, J. J., Chow, S. M., Ng, E. K., Yu, A. C., Chu, E. S., Hui, A. M., and Leung, W. K. 2006. Diagnosis of gastric cancer by serum proteomic fingerprinting. Gastroenterology, 130(6): 1858–64.PubMedGoogle Scholar
  161. Powell, S. M., Cummings, O. W., Mullen, J. A., Asghar, A., Fuga, G., Piva, P., Minacci, C., Megha, T., Tosi, P., and Jackson, C. E. 1996. Characterization of the APC gene in sporadic gastric adenocarcinomas. Oncogene, 12(9): 1953–9.PubMedGoogle Scholar
  162. Powell, S. M., Harper, J. C., Hamilton, S. R., Robinson, C. R., and Cummings, O. W. 1997. Inactivation of Smad4 in gastric carcinomas. Cancer Res, 57(19): 4221–4.PubMedGoogle Scholar
  163. Powell, S. M., and Smith, M. F., Jr. 2002. Gastric Cancer: molecular biology. In: Kelsen, D.P., editor. Gastrointestinal oncology: principle and practice. Philadelphia: Lippincott Williams & Wilkins; pp. 325–40.Google Scholar
  164. Ramesh, S., Nash, J., and McCulloch, P. G. 1999. Reduction in membranous expression of beta-catenin and increased cytoplasmic E-cadherin expression predict poor survival in gastric cancer. Br J Cancer, 81(8): 1392–7.PubMedGoogle Scholar
  165. Renkonen-Sinisalo, L., Sipponen, P., Aarnio, M., Julkunen, R., Aaltonen, L. A., Sarna, S., Jarvinen, H. J., and Mecklin, J. P. 2002. No support for endoscopic surveillance for gastric cancer in hereditary non-polyposis colorectal cancer. Scand J Gastroenterol, 37(5): 574–7.PubMedGoogle Scholar
  166. Rhyu, M. G., Park, W. S., Jung, Y. J., Choi, S. W., and Meltzer, S. J. 1994. Allelic deletions of MCC/APC and p53 are frequent late events in human gastric carcinogenesis. Gastroenterology, 106(6): 1584–8.PubMedGoogle Scholar
  167. Rumpel, C. A., Powell, S. M., and Moskaluk, C. A. 1999. Mapping of genetic deletions on the long arm of chromosome 4 in human esophageal adenocarcinomas. Am J Pathol, 154(5): 1329–34.PubMedGoogle Scholar
  168. Saito, H., Tsujitani, S., Ikeguchi, M., Maeta, M., and Kaibara, N. 1999. Serum level of a soluble receptor for interleukin-2 as a prognostic factor in patients with gastric cancer. Oncology, 56(3): 253–8.PubMedGoogle Scholar
  169. Saito, H., Tsujitani, S., Oka, S., Kondo, A., Ikeguchi, M., Maeta, M., and Kaibara, N. 1999. The expression of thymidine phosphorylase correlates with angiogenesis and the efficacy of chemotherapy using fluorouracil derivatives in advanced gastric carcinoma. Br J Cancer, 81(3): 484–9.PubMedGoogle Scholar
  170. Sakai, T., Aoyama, N., Satonaka, K., Shigeta, S., Yoshida, H., Shinoda, Y., Shirasaka, D., Miyamoto, M., Nose, Y., and Kasuga, M. 1999. HLA-DQB1 locus and the development of atrophic gastritis with Helicobacter pylori infection. J Gastroenterol, 34(Suppl 11): 24–7.PubMedGoogle Scholar
  171. Sakakura, C., Hagiwara, A., Yasuoka, R., Fujita, Y., Nakanishi, M., Masuda, K., Shimomura, K., Nakamura, Y., Inazawa, J., Abe, T., and Yamagishi, H. 2001. Tumour-amplified kinase BTAK is amplified and overexpressed in gastric cancers with possible involvement in aneuploid formation. Br J Cancer, 84(6): 824–31.PubMedGoogle Scholar
  172. Sakakura, C., Hasegawa, K., Miyagawa, K., Nakashima, S., Yoshikawa, T., Kin, S., Nakase, Y., Yazumi, S., Yamagishi, H., Okanoue, T., Chiba, T., and Hagiwara, A. 2005. Possible involvement of RUNX3 silencing in the peritoneal metastases of gastric cancers. Clin Cancer Res, 11(18): 6479–88.PubMedGoogle Scholar
  173. Sakata, K., Tamura, G., Nishizuka, S., Maesawa, C., Suzuki, Y., Iwaya, T., Terashima, M., Saito, K., and Satodate, R. 1997. Commonly deleted regions on the long arm of chromosome 21 in differentiated adenocarcinoma of the stomach. Genes Chromosomes Cancer, 18(4): 318–21.PubMedGoogle Scholar
  174. Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S. M., Riggins, G. J., Willson, J. K., Markowitz, S., Kinzler, K. W., Vogelstein, B., and Velculescu, V. E. 2004. High frequency of mutations of the PIK3CA gene in human cancers. Science, 304(5670): 554.PubMedGoogle Scholar
  175. Sankpal, N. V., Mayo, M. W., and Powell, S. M. 2005. Transcriptional repression of TFF1 in gastric epithelial cells by CCAAT/enhancer binding protein-beta. Biochim Biophys Acta, 1728(1–2): 1–10.PubMedGoogle Scholar
  176. Sankpal, N. V., Moskaluk, C. A., Hampton, G. M., and Powell, S. M. 2006. Overexpression of CEBPbeta correlates with decreased TFF1 in gastric cancer. Oncogene, 25(4): 643–9.PubMedGoogle Scholar
  177. Sano, T., Tsujino, T., Yoshida, K., Nakayama, H., Haruma, K., Ito, H., Nakamura, Y., Kajiyama, G., and Tahara, E. 1991. Frequent loss of heterozygosity on chromosomes 1q, 5q, and 17p in human gastric carcinomas. Cancer Res, 51(11): 2926–31.PubMedGoogle Scholar
  178. Sasaki, O., Soejima, K., Korenaga, D., and Haraguchi, Y. 1999. Comparison of the intratumor DNA ploidy distribution pattern between differentiated and undifferentiated gastric carcinoma. Anal Quant Cytol Histol, 21(2): 161–5.PubMedGoogle Scholar
  179. Schneider, B. G., Pulitzer, D. R., Brown, R. D., Prihoda, T. J., Bostwick, D. G., Saldivar, V., Rodriguez-Martinez, H. A., Gutierrez-Diaz, M. E., and O'Connell, P. 1995. Allelic imbalance in gastric cancer: an affected site on chromosome arm 3p. Genes Chromosomes Cancer, 13(4): 263–71.PubMedGoogle Scholar
  180. Seruca, R., Castedo, S., Correia, C., Gomes, P., Carneiro, F., Soares, P., de Jong, B., and Sobrinho-Simoes, M. 1993. Cytogenetic findings in eleven gastric carcinomas. Cancer Genet Cytogenet, 68(1): 42–8.PubMedGoogle Scholar
  181. Sheu, M. J., Yang, H. B., Sheu, B. S., Cheng, H. C., Lin, C. Y., and Wu, J. J. 2006. Erythrocyte Lewis (A+B−) host phenotype is a factor with familial clustering for increased risk of Helicobacter pylori-related non-cardiac gastric cancer. J Gastroenterol Hepatol, 21(6): 1054–8.PubMedGoogle Scholar
  182. Shinmura, K., Kohno, T., Takahashi, M., Sasaki, A., Ochiai, A., Guilford, P., Hunter, A., Reeve, A. E., Sugimura, H., Yamaguchi, N., and Yokota, J. 1999. Familial gastric cancer: clinico-pathological characteristics, RER phenotype and germline p53 and E-cadherin mutations. Carcinogenesis, 20(6): 1127–31.PubMedGoogle Scholar
  183. Souza, R. F., Appel, R., Yin, J., Wang, S., Smolinski, K. N., Abraham, J. M., Zou, T. T., Shi, Y. Q., Lei, J., Cottrell, J., Cymes, K., Biden, K., Simms, L., Leggett, B., Lynch, P. M., Frazier, M., Powell, S. M., Harpaz, N., Sugimura, H., Young, J., and Meltzer, S. J. 1996. Microsatellite instability in the insulin-like growth factor II receptor gene in gastrointestinal tumours. Nat Genet, 14(3): 255–7.PubMedGoogle Scholar
  184. Souza, R. F., Yin, J., Smolinski, K. N., Zou, T. T., Wang, S., Shi, Y. Q., Rhyu, M. G., Cottrell, J., Abraham, J. M., Biden, K., Simms, L., Leggett, B., Bova, G. S., Frank, T., Powell, S. M., Sugimura, H., Young, J., Harpaz, N., Shimizu, K., Matsubara, N., and Meltzer, S. J. 1997. Frequent mutation of the E2F-4 cell cycle gene in primary human gastrointestinal tumors. Cancer Res, 57(12): 2350–3.PubMedGoogle Scholar
  185. Stone, J., Bevan, S., Cunningham, D., Hill, A., Rahman, N., Peto, J., Marossy, A., and Houlston, R. S. 1999. Low frequency of germline E-cadherin mutations in familial and nonfamilial gastric cancer. Br J Cancer, 79(11–12): 1935–7.PubMedGoogle Scholar
  186. Strickler, J. G., Zheng, J., Shu, Q., Burgart, L. J., Alberts, S. R., and Shibata, D. 1994. P53 mutations and microsatellite instability in sporadic gastric cancer: when guardians fail. Cancer Res, 54(17): 4750–5.PubMedGoogle Scholar
  187. Suzuki, H., Itoh, F., Toyota, M., Kikuchi, T., Kakiuchi, H., Hinoda, Y., and Imai, K. 1999. Distinct methylation pattern and microsatellite instability in sporadic gastric cancer. J Int Cancer, 83(3): 309–13.Google Scholar
  188. Taha, A. S., Curry, G. W., Morton, R., Park, R. H., and Beattie, A. D. 1996. Gastric mucosal hepatocyte growth factor in Helicobacter pylori gastritis and peptic ulcer disease. Am J Gastroenterol, 91(7): 1407–9.PubMedGoogle Scholar
  189. Tahara, E. 1995. Molecular biology of gastric cancer. World J Surg, 19(4): 484–8; discussion 489–90.PubMedGoogle Scholar
  190. Tahara, E., Semba, S., and Tahara, H. 1996. Molecular biological observations in gastric cancer. Semin Oncol, 23(3): 307–15.PubMedGoogle Scholar
  191. Takano, Y., Kato, Y., Masuda, M., Ohshima, Y., and Okayasu, I. 1999. Cyclin D2, but not cyclin D1, overexpression closely correlates with gastric cancer progression and prognosis. J Pathol, 189(2): 194–200.PubMedGoogle Scholar
  192. Tamura, G. 2004. Promoter methylation status of tumor suppressor and tumor-related genes in neoplastic and non-neoplastic gastric epithelia. Histol Histopathol, 19(1): 221–8.PubMedGoogle Scholar
  193. Tamura, G., Ogasawara, S., Nishizuka, S., Sakata, K., Maesawa, C., Suzuki, Y., Terashima, M., Saito, K., and Satodate, R. 1996. Two distinct regions of deletion on the long arm of chromosome 5 in differentiated adenocarcinomas of the stomach. Cancer Res, 56(3): 612–5.PubMedGoogle Scholar
  194. Taniguchi, K., Yonemura, Y., Nojima, N., Hirono, Y., Fushida, S., Fujimura, T., Miwa, K., Endo, Y., Yamamoto, H., and Watanabe, H. 1998. The relation between the growth patterns of gastric carcinoma and the expression of hepatocyte growth factor receptor (c-met), autocrine motility factor receptor, and urokinase-type plasminogen activator receptor. Cancer, 82(11): 2112–22.PubMedGoogle Scholar
  195. Tateishi, M., Toda, T., Minamisono, Y., and Nagasaki, S. 1992. Clinicopathological significance of c-erbB-2 protein expression in human gastric carcinoma. J Surg Oncol, 49(4): 209–12.PubMedGoogle Scholar
  196. Tebbutt, N. C., Giraud, A. S., Inglese, M., Jenkins, B., Waring, P., Clay, F. J., Malki, S., Alderman, B. M., Grail, D., Hollande, F., Heath, J. K., and Ernst, M. 2002. Reciprocal regulation of gastrointestinal homeostasis by SHP2 and STAT-mediated trefoil gene activation in gp130 mutant mice. Nat Med, 8(10): 1089–97.PubMedGoogle Scholar
  197. Tokunaga, A., Onda, M., Okuda, T., Teramoto, T., Fujita, I., Mizutani, T., Kiyama, T., Yoshiyuki, T., Nishi, K., and Matsukura, N. 1995. Clinical significance of epidermal growth factor (EGF), EGF receptor, and c-erbB-2 in human gastric cancer. Cancer, 75(6 Suppl): 1418–25.PubMedGoogle Scholar
  198. Torii, A., Kodera, Y., Uesaka, K., Hirai, T., Yasui, K., Morimoto, T., Yamamura, Y., Kato, T., Hayakawa, T., Fujimoto, N., and Kito, T. 1997. Plasma concentration of matrix metalloprotei-nase 9 in gastric cancer. Br J Surg, 84(1): 133–6.PubMedGoogle Scholar
  199. Toyota, M., Ahuja, N., Suzuki, H., Itoh, F., Ohe-Toyota, M., Imai, K., Baylin, S. B., and Issa, J. P. 1999. Aberrant methylation in gastric cancer associated with the CpG island methylator phe-notype. Cancer Res, 59(21): 5438–42.PubMedGoogle Scholar
  200. Tsugawa, K., Yonemura, Y., Hirono, Y., Fushida, S., Kaji, M., Miwa, K., Miyazaki, I., and Yamamoto, H. 1998. Amplification of the c-met, c-erbB-2 and epidermal growth factor receptor gene in human gastric cancers: correlation to clinical features. Oncology, 55(5): 475–81.PubMedGoogle Scholar
  201. Tsuji, S., Kawano, S., Sawaoka, H., Takei, Y., Kobayashi, I., Nagano, K., Fusamoto, H., and Kamada, T. 1996. Evidences for involvement of cyclooxygenase-2 in proliferation of two gastrointestinal cancer cell lines. Prostaglandins Leukot Essent Fatty Acids, 55(3): 179–83.PubMedGoogle Scholar
  202. Uchino, S., Tsuda, H., Maruyama, K., Kinoshita, T., Sasako, M., Saito, T., Kobayashi, M., and Hirohashi, S. 1993. Overexpression of c-erbB-2 protein in gastric cancer. its correlation with long-term survival of patients. Cancer, 72(11): 3179–84.PubMedGoogle Scholar
  203. Uchino, S., Tsuda, H., Noguchi, M., Yokota, J., Terada, M., Saito, T., Kobayashi, M., Sugimura, T., and Hirohashi, S. 1992. Frequent loss of heterozygosity at the DCC locus in gastric cancer. Cancer Res, 52(11): 3099–102.PubMedGoogle Scholar
  204. Ueki, T., Koji, T., Tamiya, S., Nakane, P. K., and Tsuneyoshi, M. 1995. Expression of basic fibroblast growth factor and fibroblast growth factor receptor in advanced gastric carcinoma. J Pathol, 177(4): 353–61.PubMedGoogle Scholar
  205. Utsunomiya J. 1990. The concept of hereditary colorectal cancer and the implications of its study. Hereditary Colorectal Cancer, 3–16.Google Scholar
  206. Varis, A., van Rees, B., Weterman, M., Ristimaki, A., Offerhaus, J., and Knuutila, S. 2003. DNA copy number changes in young gastric cancer patients with special reference to chromosome 19. Br J Cancer, 88(12): 1914–9.PubMedGoogle Scholar
  207. Varley, J. M., McGown, G., Thorncroft, M., Tricker, K. J., Teare, M. D., Santibanez-Koref, M. F., Martin, J., Birch, J. M., and Evans, D. G. 1995. An extended Li-Fraumeni kindred with gastric carcinoma and a codon 175 mutation in TP53. J Med Genet, 32(12): 942–5.PubMedGoogle Scholar
  208. Videbaek, A., and Mosbech, J. 1954. The aetiology of gastric carcinoma elucidated by a study of 302 pedigrees. Acta Med Scand, 149(2): 137–59.PubMedGoogle Scholar
  209. Vivanco, I., and Sawyers, C. L. 2002. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nature reviews. Cancer, 2(7): 489–501.PubMedGoogle Scholar
  210. Wang, Z., Shen, D., Parsons, D. W., Bardelli, A., Sager, J., Szabo, S., Ptak, J., Silliman, N., Peters, B. A., van der Heijden, M. S., Parmigiani, G., Yan, H., Wang, T. L., Riggins, G., Powell, S. M., Willson, J. K., Markowitz, S., Kinzler, K. W., Vogelstein, B., and Velculescu, V. E. 2004. Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science, 304(5674): 1164–6.PubMedGoogle Scholar
  211. Weiss, M. M., Kuipers, E. J., Postma, C., Snijders, A. M., Pinkel, D., Meuwissen, S. G., Albertson, D., and Meijer, G. A. 2004. Genomic alterations in primary gastric adenocarcinomas correlate with clinicopathological characteristics and survival. Cell Oncol, 26(5–6): 307–17.PubMedGoogle Scholar
  212. Wong, D. J., Barrett, M. T., Stoger, R., Emond, M. J., and Reid, B. J. 1997. p16INK4a promoter is hypermethylated at a high frequency in esophageal adenocarcinomas. Cancer Res, 57(13): 2619–22.PubMedGoogle Scholar
  213. Wong, S. C., Yu, H., and So, J. B. 2006. Detection of telomerase activity in gastric lavage fluid: a novel method to detect gastric cancer. J Surg Res, 131(2): 252–5.PubMedGoogle Scholar
  214. Woolf, C. M., and Isaacson, E. A. 1961. An analysis of 5 “stomach cancer families” in the state of Utah. Cancer, 14: 1005–16.PubMedGoogle Scholar
  215. Wu, C. W., Lin, Y. Y., Chen, G. D., Chi, C. W., Carbone, D. P., and Chen, J. Y. 1999. Serum anti-p53 antibodies in gastric adenocarcinoma patients are associated with poor prognosis, lymph node metastasis and poorly differentiated nuclear grade. Br J Cancer, 80(3–4): 483–8.PubMedGoogle Scholar
  216. Wu, M. S., Lee, C. W., Shun, C. T., Wang, H. P., Lee, W. J., Sheu, J. C., and Lin, J. T. 1998. Clinicopathological significance of altered loci of replication error and microsatellite instability-associated mutations in gastric cancer. Cancer Res, 58(7): 1494–7.PubMedGoogle Scholar
  217. Wu, M. S., Shun, C. T., Wang, H. P., Lee, W. J., Wang, T. H., and Lin, J. T. 1998. Loss of pS2 protein expression is an early event of intestinal-type gastric cancer. Jpn J Cancer Res 89(3): 278–82.PubMedGoogle Scholar
  218. Wu, C. Y., Wu, M. S., Chiang, E. P., Wu, C. C., Chen, Y. J., Chen, C. J., Chi, N. H., Chen, G. H., and Lin, J. T. 2007. Elevated plasma osteopontin associated with gastric cancer development, invasion and survival. Gut, 56(6): 782–9.PubMedGoogle Scholar
  219. Xiangming, C., Hokita, S., Natsugoe, S., Tanabe, G., Baba, M., Takao, S., Kuroshima, K., and Aikou, T. 1999. Cooccurrence of reduced expression of alpha-catenin and overexpression of p53 is a predictor of lymph node metastasis in early gastric cancer. Oncology, 57(2): 131–7.PubMedGoogle Scholar
  220. Yamamichi, K., Uehara, Y., Kitamura, N., Nakane, Y., and Hioki, K. 1998. Increased expression of CD44v6 mRNA significantly correlates with distant metastasis and poor prognosis in gastric cancer. Int J Cancer, 79(3): 256–62.PubMedGoogle Scholar
  221. Yamamoto, H., Itoh, F., Fukushima, H., Adachi, Y., Itoh, H., Hinoda, Y., and Imai, K. 1999a. Frequent bax frameshift mutations in gastric cancer with high but not low microsatellite instability. J Exp Clin Cancer Res, 18(1): 103–6.Google Scholar
  222. Yamamoto, H., Perez-Piteira, J., Yoshida, T., Terada, M., Itoh, F., Imai, K., and Perucho, M. 1999b. Gastric cancers of the microsatellite mutator phenotype display characteristic genetic and clinical features. Gastroenterology, 116(6): 1348–57.Google Scholar
  223. Yamamoto, H., Sawai, H., and Perucho, M. 1997. Frameshift somatic mutations in gastrointestinal cancer of the microsatellite mutator phenotype. Cancer Res, 57(19): 4420–6.PubMedGoogle Scholar
  224. Yasunaga, Y., Shinomura, Y., Kanayama, S., Higashimoto, Y., Yabu, M., Miyazaki, Y., Kondo, S., Murayama, Y., Nishibayashi, H., Kitamura, S., and Matsuzawa, Y. 1996. Increased production of interleukin 1 beta and hepatocyte growth factor may contribute to foveolar hyperplasia in enlarged fold gastritis. Gut, 39(96): 787–94.PubMedGoogle Scholar
  225. Yin, J., Kong, D., Wang, S., Zou, T. T., Souza, R. F., Smolinski, K. N., Lynch, P. M., Hamilton, S. R., Sugimura, H., Powell, S. M., Young, J., Abraham, J. M., and Meltzer, S. J. 1997. Mutation of hMSH3 and hMSH6 mismatch repair genes in genetically unstable human colorectal and gastric carcinomas. Human Mutat, 10(6): 474–8.Google Scholar
  226. Yonemura, Y., Ninomiya, I., Yamaguchi, A., Fushida, S., Kimura, H., Ohoyama, S., Miyazaki, I., Endou, Y., Tanaka, M., and Sasaki, T. 1991. Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer. Cancer Res, 51(3): 1034–8.PubMedGoogle Scholar
  227. Yoon, K. A., Ku, J. L., Yang, H. K., Kim, W. H., Park, S. Y., and Park, J. G. 1999. Germline mutations of E-cadherin gene in Korean familial gastric cancer patients. J Hum Genet, 44(3): 177–80.PubMedGoogle Scholar
  228. Yoshikawa, T., Saitoh, M., Tsuburaya, A., Kobayashi, O., Sairenji, M., Motohashi, H., Yanoma, S., and Noguchi, Y. 1999. Tissue inhibitor of matrix metalloproteinase-1 in the plasma of patients with gastric carcinoma. A possible marker for serosal invasion and metastasis. Cancer, 86(10): 1929–35.Google Scholar
  229. Yustein, A. S., Harper, J. C., Petroni, G. R., Cummings, O. W., Moskaluk, C. A., and Powell, S. M. 1999. Allelotype of gastric adenocarcinoma. Cancer Res, 59(7): 1437–41.PubMedGoogle Scholar
  230. Zafirellis, K., Karameris, A., Milingos, N., and Androulakis, G. 2005. Molecular markers in gastric cancer: can p53 and bcl-2 protein expressions be used as prognostic factors? Anticancer Res, 25(5): 3629–36.PubMedGoogle Scholar
  231. Zanghieri, G., Di Gregorio, C., Sacchetti, C., Fante, R., Sassatelli, R., Cannizzo, G., Carriero, A., and Ponz de Leon, M. 1990. Familial occurrence of gastric cancer in the 2-year experience of a population-based registry. Cancer, 66(9): 2047–51.PubMedGoogle Scholar
  232. Zhang, Y., Liu, X., Fan, Y., Ding, J., Xu, A., Zhou, X., Hu, X., Zhu, M., Zhang, X., Li, S., Wu, J., Cao, H., Li, J., and Wang, Y. 2006. Germline mutations and polymorphic variants in MMR, E-cadherin and MYH genes associated with familial gastric cancer in Jiangsu of China. Int J Cancer, 119(11): 2592–6.PubMedGoogle Scholar
  233. Zou, B., Chim, C. S., Zeng, H., Leung, S. Y., Yang, Y., Tu, S. P., Lin, M. C., Wang, J., He, H., Jiang, S. H., Sun, Y. W., Yu, L. F., Yuen, S. T., Kung, H. F., and Wong, B. C. 2006. Correlation between the single-site CpG methylation and expression silencing of the XAF1 gene in human gastric and colon cancers. Gastroenterology, 131(6): 1835–43.PubMedGoogle Scholar

Copyright information

© Springer Science + Business Media, LLC 2009

Authors and Affiliations

  • Roman GalyshJr.
    • 1
  • Steven M. Powell
    • 2
  1. 1.Gastroenterology Fellow, Department of Medicine, Division of Gastroenterology/ HepatologyUniversity of Virginia Health SystemCharlottesvilleUSA
  2. 2.Division of Gastroenterology/HepatologyUniversity of Virginia Health SystemCharlottesvilleUSA

Personalised recommendations